Compare XAIR & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XAIR | SHPH |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.2M |
| IPO Year | 2015 | 2022 |
| Metric | XAIR | SHPH |
|---|---|---|
| Price | $0.50 | $1.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 336.8K | 168.2K |
| Earning Date | 06-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,705,000.00 | N/A |
| Revenue This Year | $122.00 | N/A |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 219.67 | N/A |
| 52 Week Low | $0.15 | $0.12 |
| 52 Week High | $3.78 | $5.59 |
| Indicator | XAIR | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 54.79 |
| Support Level | $0.43 | $0.80 |
| Resistance Level | $0.82 | $1.13 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 17.29 | 64.81 |
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.